advancing medicines for a brighter future
Biotechnology Research
Cardiff, cardiff
Founded in 2000
11-50 employees
biodexa pharmaceuticals plc (listed on nasdaq: bdrx) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. the company’s lead candidate, mtx110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. mtx110 is a solubilised formulation of the histone deacetylase (hdac) inhibitor, panobinostat. this proprietary formulation enables delivery of the product via convection-enhanced delivery (ced) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.
Company Information
- Industry
- Biotechnology Research
- Company Type
- Public Company
- Founded
- 2000
- Employee Range
- 11-50
- Revenue Range
- Not available
Location
- Address
- 1 caspian point
- City
- Cardiff
- Region
- cardiff
- Postal Code
- cf10 4dq
- Country
- United Kingdom
Web Presence
Websitebiodexapharma.com
LinkedIn3,670 followers
TwitterView Profile
FacebookView Page
CrunchbaseView Profile
